An ascending single and multiple dose study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of HKI-272 [neratinib] administered orally to subjects with HER-2/NEU or HER-1/EGFR [epidermal growth factor receptor]-positive tumors
Phase of Trial: Phase I
Latest Information Update: 25 Sep 2018
At a glance
- Drugs Neratinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Puma Biotechnology
- 11 May 2012 Additional company (Puma Biotechnology) added in association as reported by ClinicalTrials.gov.
- 04 Dec 2007 Status changed from in progress to completed as reported on clinicaltrials.gov website.
- 07 Nov 2005 New trial record.